Versartis Inc. said Chief Development Officer Colin Hislop's employment will be terminated, effective Oct. 20.
Hislop joined Versartis in 2016 from Anthera Pharmaceuticals Inc., where he served as the company's chief medical officer.
Versartis chief development officer to leave
COVID-19 Pandemic Likely To Cause US Telemedicine Boom
Gauging Supply Chain Risk In Volatile Times
Cannabis: Hashing Out a Budding Industry
IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help
Versartis chief development officer to leave
- Author Kshitiz Goliya
- Theme Healthcare & Pharmaceuticals
- Author
- Kshitiz Goliya
- Theme
- Healthcare & Pharmaceuticals